Literature DB >> 25855481

An Unusual Case of Statin-Induced Myopathy: Anti-HMGCoA Necrotizing Autoimmune Myopathy.

Laura Nichols1, Kurt Pfeifer2, Andrew L Mammen3,4,5, Nazima Shahnoor6, Chamindra G Konersman6,7.   

Abstract

Statins are some of the most widely prescribed medications, and though generally well tolerated, can lead to a self-limited myopathy in a minority of patients. Recently, these medications have been associated with a necrotizing autoimmune myopathy (NAM). Statin-associated NAM is characterized by irritable myopathy on electromyography (EMG) and muscle necrosis with minimal inflammation on muscle biopsy. The case presented is a 63-year-old woman who has continued elevation of creatine kinase (CK) after discontinuation of statin therapy. She has irritable myopathy on EMG and NAM is confirmed by muscle biopsy. She subsequently tests positive for an experimental anti-3-hydroxy-3-methylglutaryl-coenzyme A (anti-HMGCoA) antibody that is found to be present in patients with statin-associated NAM. Though statin-associated NAM is a relatively rare entity, it is an important consideration for the general internist in patients who continue to have CK elevation and weakness after discontinuation of statin therapy. Continued research is necessary to better define statin-specific and dose-dependent risk, as well as optimal treatment for this condition.

Entities:  

Keywords:  anti-HMGCR antibody; idiopathic inflammatory myopathy; necrotizing autoimmune myopathy; statin

Mesh:

Substances:

Year:  2015        PMID: 25855481      PMCID: PMC4636568          DOI: 10.1007/s11606-015-3303-9

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  17 in total

1.  A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.

Authors:  Lisa Christopher-Stine; Livia A Casciola-Rosen; Grace Hong; Tae Chung; Andrea M Corse; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2010-09

2.  An assessment of statin safety by muscle experts.

Authors:  Paul D Thompson; Priscilla M Clarkson; Robert S Rosenson
Journal:  Am J Cardiol       Date:  2006-02-09       Impact factor: 2.778

Review 3.  Statin induced myopathy.

Authors:  Sivakumar Sathasivam; Bryan Lecky
Journal:  BMJ       Date:  2008-11-06

4.  More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines.

Authors:  John P A Ioannidis
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

5.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

6.  Progressive myopathy with up-regulation of MHC-I associated with statin therapy.

Authors:  Merrilee Needham; Victoria Fabian; Wally Knezevic; Peter Panegyres; Paul Zilko; Frank L Mastaglia
Journal:  Neuromuscul Disord       Date:  2007-01-22       Impact factor: 4.296

7.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

Authors:  David J Graham; Judy A Staffa; Deborah Shatin; Susan E Andrade; Stephanie D Schech; Lois La Grenade; Jerry H Gurwitz; K Arnold Chan; Michael J Goodman; Richard Platt
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

8.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

9.  Immune-mediated necrotizing myopathy associated with statins.

Authors:  Phyllis Grable-Esposito; Hans D Katzberg; Steven A Greenberg; Jayashri Srinivasan; Jonathan Katz; Anthony A Amato
Journal:  Muscle Nerve       Date:  2010-02       Impact factor: 3.217

10.  Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006.

Authors:  Mariam Molokhia; Paul McKeigue; Vasa Curcin; Azeem Majeed
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more
  6 in total

1.  Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.

Authors:  Dirk Essers; Martina Schäublin; Gerd A Kullak-Ublick; Stefan Weiler
Journal:  Eur J Clin Pharmacol       Date:  2018-11-15       Impact factor: 2.953

2.  Anti-HMGCR myopathy presenting with acute systolic heart failure.

Authors:  Mitchell Pitlick; Floranne Ernste
Journal:  BMJ Case Rep       Date:  2019-05-08

3.  A Case Report of Statin-Induced Immune-Mediated Necrotizing Myopathy Treatment Challenges.

Authors:  Anwar I Joudeh; Mhd Kutaiba Albuni; Sara Seife Hassen; Phool Iqbal; Elsaid Mohamed Aziz Bedair; Salah Mahdi
Journal:  Case Rep Rheumatol       Date:  2022-05-31

4.  Statin-induced necrotising autoimmune myopathy and autoimmune hepatitis presenting with dysphagia.

Authors:  Osama Qasim Agha; Sukhdeep Kaur; Nirmal Vijayavel
Journal:  BMJ Case Rep       Date:  2020-02-05

5.  A RARE CASE OF STATIN-INDUCED NECROTIZING AUTOIMMUNE MYOPATHY.

Authors:  Shirley Shuster; Sara Awad
Journal:  AACE Clin Case Rep       Date:  2020-01-22

6.  A Case of Atorvastatin-Associated Necrotizing Autoimmune Myopathy, Mimicking Idiopathic Polymyositis.

Authors:  Ayushi Dixit; Adriana Abrudescu
Journal:  Case Rep Rheumatol       Date:  2018-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.